AJP - Heart and Circulatory Physiology, Vol 269, Issue 2 473-H479, Copyright © 1995 by American Physiological Society

ARTICLES

Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus

J. W. Ziegler, D. D. Ivy, J. J. Fox, J. P. Kinsella, W. R. Clarke and S. H. Abman
Department of Pediatrics, Children's Hospital, Denver, Colorado, USA.

Endogenous nitric oxide (NO) modulates fetal pulmonary vascular tone by stimulating guanosine 3',5'-cyclic monophosphate (cGMP) production in vascular smooth muscle. Because cGMP is hydrolyzed and inactivated by phosphodiesterase enzymes, we evaluated the hemodynamic effects of two cGMP-specific phosphodiesterase (PDE5) inhibitors, dipyridamole and zaprinast, in the near-term chronically prepared ovine fetus. Brief (10 min) intrapulmonary infusions of dipyridamole caused dose-dependent increases in left pulmonary artery flow and decreases in left pulmonary arterial resistance that persisted for > 40 min after termination of the infusion. Prolonged (2 h) infusions of dipyridamole caused sustained pulmonary vasodilation throughout the infusion period. To compare the hemodynamic effects of dipyridamole with the PDE5 antagonist zaprinast, we studied the responses to equimolar doses of both agents in four fetuses. Zaprinast caused dose-dependent pulmonary vasodilation that was equivalent to that noted with equimolar doses of dipyridamole. To determine whether adenosine is involved with dipyridamole-induced pulmonary vasodilation, we compared the hemodynamic response to dipyridamole before and after administration of the potent adenosine receptor (P1) antagonist 8-phenyltheophylline (8-PT). Pretreatment with 8-PT markedly attenuated adenosine-induced pulmonary vasodilation but had no effect on the hemodynamic response to dipyridamole. We conclude that cGMP-specific phosphodiesterase activity is important in regulating fetal pulmonary vascular tone. In addition, dipyridamole administration causes dose-dependent pulmonary vasodilation that is equivalent to zaprinast and not primarily due to its effects on adenosine.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				R. C. Dukarm, R. H. Steinhorn, J. A. Russell, S. Lakshminrusimha, D. Swartz, and J. J. Cummings Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs J Appl Physiol, December 1, 2005; 99(6): 2331 - 2336. [Abstract] [Full Text] [PDF]

				P. Deruelle, T. R. Grover, L. Storme, and S. H. Abman Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L727 - L733. [Abstract] [Full Text] [PDF]

				Z. Y. Jiang, T. Costachescu, M. Derouin, and G. Blaise Treatment of pulmonary hypertension during surgery with nitric oxide and vasodilators Can J Anesth, June 1, 2000; 47(6): 552 - 555. [Abstract] [Full Text] [PDF]

				B. Thebaud, P. de Lagausie, D. Forgues, Y. Aigrain, J.-C. Mercier, and A. T. Dinh-Xuan ETA-receptor blockade and ETB-receptor stimulation in experimental congenital diaphragmatic hernia Am J Physiol Lung Cell Mol Physiol, May 1, 2000; 278(5): L923 - L932. [Abstract] [Full Text] [PDF]

				D. N. Cornfield, R. C. Maynard, R.-A. O. deRegnier, S. F. Guiang III, J. E. Barbato, and C. E. Milla Randomized, Controlled Trial of Low-dose Inhaled Nitric Oxide in the Treatment of Term and Near-term Infants With Respiratory Failure and Pulmonary Hypertension Pediatrics, November 1, 1999; 104(5): 1089 - 1094. [Abstract] [Full Text]

				G. Barba, M. J. Mullen, A. Donald, and R. J. MacAllister Determinants of the Response of Human Blood Vessels to Nitric Oxide Donors In Vivo J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1662 - 1668. [Abstract] [Full Text]

				J. W. ZIEGLER, D. D. IVY, J. W. WIGGINS, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN Effects of Dipyridamole and Inhaled Nitric Oxide in Pediatric Patients with Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1998; 158(5): 1388 - 1395. [Abstract] [Full Text] [PDF]

				K. A. Hanson, J. W. Ziegler, S. D. Rybalkin, J. W. Miller, S. H. Abman, and W. R. Clarke Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity Am J Physiol Lung Cell Mol Physiol, November 1, 1998; 275(5): L931 - L941. [Abstract] [Full Text] [PDF]

				K. A. HANSON, F. BURNS, S. D. RYBALKIN, J. W. MILLER, J. BEAVO, and W. R. CLARKE Developmental Changes in Lung cGMP Phosphodiesterase-5 Activity, Protein, and Message Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 279 - 288. [Abstract] [Full Text] [PDF]

				D. D. Ivy, J. P. Kinsella, J. W. Ziegler, and S. H. Abman Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease J. Thorac. Cardiovasc. Surg., April 1, 1998; 115(4): 875 - 882. [Abstract] [Full Text] [PDF]

				J. W. ZIEGLER, D. DUNBAR IVY, J. J. FOX, J. P. KINSELLA, W. R. CLARKE, and S. H. ABMAN Dipyridamole Potentiates Pulmonary Vasodilation Induced by Acetylcholine and Nitric Oxide in the Ovine Fetus Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1104 - 1110. [Abstract] [Full Text] [PDF]

				D. B. Pearse, T. E. Dahms, and E. M. Wagner Microsphere-induced bronchial artery vasodilation: role of adenosine, prostacyclin, and nitric oxide Am J Physiol Heart Circ Physiol, March 1, 1998; 274(3): H760 - H768. [Abstract] [Full Text] [PDF]

				D. A. Fullerton, J. Jaggers, F. Piedalue, F. L. Grover, and R. C. McIntyre Jr. EFFECTIVE CONTROL OF REFRACTORY PULMONARY HYPERTENSION AFTER CARDIAC OPERATIONS J. Thorac. Cardiovasc. Surg., February 1, 1997; 113(2): 363 - 370. [Abstract] [Full Text]

				N. L. Jernigan and T. C. Resta Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1366 - L1375. [Abstract] [Full Text] [PDF]